APVAC1 vaccine

APVAC1 is a personalized peptide-based cancer vaccine developed for the treatment of newly diagnosed glioblastoma. It is composed of up to seven nonmutated HLA class I peptides, two pan-DR binding HLA class II-restricted tumor-associated peptides, and one HLA class I viral marker peptide. These peptides are selected from a pre-manufactured library based on the individual patient's tumor peptidome and transcriptome analysis. The goal is to stimulate the host immune system—specifically cytotoxic T-lymphocyte (CTL) responses—against tumor-associated antigens that are overexpressed in glioma cells but not mutated. The vaccine is administered with immunomodulatory adjuvants poly-ICLC (polyriboinosinic-polyribocytidylic acid-poly-L-lysine carboxymethylcellulose) and granulocyte-macrophage colony-stimulating factor (GM-CSF). In phase 1 clinical trials, APVAC1 demonstrated high immunogenicity, eliciting sustained central memory CD8+ T cell responses and was well tolerated without serious treatment-related adverse events[2][3][4][5][6].

Other names

synthetic glioblastoma tumor-associated peptides vaccine therapy APVAC1